Samsung Biologics Co.,Ltd.

KOSE:A207940 Stock Report

Market Cap: ₩58.4t

Samsung BiologicsLtd Valuation

Is A207940 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • PM vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A207940 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A207940 (₩819000) is trading above our estimate of fair value (₩304460.69)

Significantly Below Fair Value: A207940 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A207940?

Other financial metrics that can be useful for relative valuation.

A207940 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue16.4x
Enterprise Value/EBITDA38.8x
PEG Ratio5x

Price to Earnings Ratio vs Peers

How does A207940's PE Ratio compare to its peers?

The above table shows the PE ratio for A207940 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average66x
A237690 ST PharmLtd
103x60.0%₩1.2t
A068270 Celltrion
62.8x37.5%₩38.4t
ICLR ICON
46.4x17.0%US$23.8b
LONN Lonza Group
51.8x18.8%CHF33.9b
A207940 Samsung BiologicsLtd
62.2x12.3%₩58.4t

Price-To-Earnings vs Peers: A207940 is good value based on its Price-To-Earnings Ratio (62.2x) compared to the peer average (66x).


Price to Earnings Ratio vs Industry

How does A207940's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: A207940 is expensive based on its Price-To-Earnings Ratio (62.2x) compared to the Asian Life Sciences industry average (28.2x).


Price to Earnings Ratio vs Fair Ratio

What is A207940's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A207940 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio62.2x
Fair PE Ratio30.4x

PM vs Fair Ratio: A207940 is expensive based on its Price-To-Earnings Ratio (62.2x) compared to the estimated Fair Price-To-Earnings Ratio (30.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A207940 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩819,000.00
₩1,035,309.36
+26.4%
8.7%₩1,250,000.00₩750,000.00n/a25
Feb ’25₩829,000.00
₩1,035,309.36
+24.9%
8.7%₩1,250,000.00₩750,000.00n/a25
Jan ’25₩760,000.00
₩1,035,309.36
+36.2%
9.8%₩1,250,000.00₩720,000.00n/a25
Dec ’24₩711,000.00
₩1,035,309.36
+45.6%
9.8%₩1,250,000.00₩720,000.00n/a25
Nov ’24₩703,000.00
₩1,036,780.58
+47.5%
9.9%₩1,250,000.00₩720,000.00n/a24
Oct ’24₩681,000.00
₩1,052,292.78
+54.5%
9.3%₩1,250,000.00₩770,000.00n/a23
Sep ’24₩733,000.00
₩1,058,030.58
+44.3%
7.7%₩1,160,000.00₩770,000.00n/a24
Aug ’24₩802,000.00
₩1,068,951.31
+33.3%
8.1%₩1,200,000.00₩770,000.00n/a26
Jul ’24₩744,000.00
₩1,082,766.62
+45.5%
8.8%₩1,200,000.00₩770,000.00n/a26
Jun ’24₩788,000.00
₩1,082,766.62
+37.4%
8.8%₩1,200,000.00₩770,000.00n/a26
May ’24₩781,000.00
₩1,091,228.15
+39.7%
8.6%₩1,200,000.00₩770,000.00n/a26
Apr ’24₩788,000.00
₩1,101,612.77
+39.8%
8.7%₩1,300,000.00₩770,000.00n/a26
Mar ’24₩773,000.00
₩1,112,211.86
+43.9%
8.7%₩1,300,000.00₩770,000.00n/a28
Feb ’24₩804,000.00
₩1,114,711.86
+38.6%
8.8%₩1,300,000.00₩770,000.00₩829,000.0028
Jan ’24₩821,000.00
₩1,111,055.65
+35.3%
8.2%₩1,300,000.00₩830,000.00₩760,000.0026
Dec ’23₩884,000.00
₩1,111,055.65
+25.7%
8.2%₩1,300,000.00₩830,000.00₩711,000.0026
Nov ’23₩882,000.00
₩1,114,349.89
+26.3%
8.2%₩1,300,000.00₩830,000.00₩703,000.0027
Oct ’23₩807,000.00
₩1,101,976.96
+36.6%
6.1%₩1,200,000.00₩987,447.00₩681,000.0024
Sep ’23₩826,000.00
₩1,109,889.00
+34.4%
5.8%₩1,200,000.00₩987,447.00₩733,000.0023
Aug ’23₩878,000.00
₩1,104,697.88
+25.8%
6.9%₩1,240,000.00₩970,000.00₩802,000.0025
Jul ’23₩781,000.00
₩1,092,146.55
+39.8%
8.5%₩1,250,000.00₩870,000.00₩744,000.0022
Jun ’23₩847,000.00
₩1,089,444.52
+28.6%
8.5%₩1,250,000.00₩870,000.00₩788,000.0023
May ’23₩838,000.00
₩1,086,692.00
+29.7%
8.6%₩1,250,000.00₩870,000.00₩781,000.0022
Apr ’23₩820,000.00
₩1,087,361.99
+32.6%
9.3%₩1,250,000.00₩859,819.73₩788,000.0021
Mar ’23₩779,000.00
₩1,094,522.00
+40.5%
8.6%₩1,250,000.00₩870,000.00₩773,000.0022
Feb ’23₩739,000.00
₩1,094,522.00
+48.1%
8.6%₩1,250,000.00₩870,000.00₩804,000.0022

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.